NASDAQ:BGLC BioNexus Gene Lab (BGLC) Stock Price, News & Analysis $0.77 -0.05 (-6.58%) As of 11:11 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsNews and TrendsOwnershipSEC Filings About BioNexus Gene Lab Stock (NASDAQ:BGLC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BioNexus Gene Lab alerts:Sign Up Key Stats Today's Range$0.80▼$0.8250-Day Range$0.81▼$1.6152-Week Range$0.80▼$4.97Volume1,028 shsAverage Volume38,324 shsMarket Capitalization$2.25 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview BioNexus Gene Lab Corp. is a Malaysia-focused company with businesses in medical diagnostics and chemical distribution. Through its laboratory operations, it provides molecular and genetic testing services to support healthcare assessment and decision-making. The company also distributes industrial and specialty chemicals through its subsidiary, Chemrex Corporation. Its products serve business customers in sectors that use chemicals in manufacturing and related applications. BioNexus Gene Lab’s operations are primarily based in Malaysia. The company’s activities combine diagnostic testing services with the distribution of chemicals to commercial customers.AI Generated. May Contain Errors. Read More BioNexus Gene Lab Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks22nd Percentile Overall ScoreBGLC MarketRank™: 1.09096945551 of 5 starsBioNexus Gene Lab scored higher than 22% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingBioNexus Gene Lab has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageBioNexus Gene Lab has only been the subject of 1 research reports in the past 90 days.Read more about BioNexus Gene Lab's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of BioNexus Gene Lab is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioNexus Gene Lab is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioNexus Gene Lab has a P/B Ratio of 0.23. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.11% of the float of BioNexus Gene Lab has been sold short.Short Interest Ratio / Days to CoverBioNexus Gene Lab has a short interest ratio ("days to cover") of 0.96, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioNexus Gene Lab has recently decreased by 64.87%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioNexus Gene Lab does not currently pay a dividend.Dividend GrowthBioNexus Gene Lab does not have a long track record of dividend growth. News and Social Media3.2 / 5News Sentiment1.19 News SentimentBioNexus Gene Lab has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Industrials companies.News Coverage This WeekMarketBeat has tracked 3 news articles for BioNexus Gene Lab this week, compared to 1 article on an average week. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BioNexus Gene Lab insiders have not sold or bought any company stock.Percentage Held by Insiders0.05% of the stock of BioNexus Gene Lab is held by insiders.Percentage Held by Institutions18.85% of the stock of BioNexus Gene Lab is held by institutions.Read more about BioNexus Gene Lab's insider trading history. Receive BGLC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioNexus Gene Lab and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BGLC Stock News HeadlinesBioNexus Gene Lab (NASDAQ:BGLC) Shares Up 7.5% - Should You Buy?November 10, 2026 | americanbankingnews.comBionexus Gene Lab Corp. and Mrna Scientific Sdn. Bhd. Launch Bglc 1Lab Pilot for Genematrix WorkflowsNovember 5, 2026 | marketscreener.comMMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment that covers a full year, with no subscription and no re-bills. Every night after the close, the scanner screens nearly a thousand of America's biggest stocks. It returns a short list of qualifying setups with the exact buy price next to each one. There's nothing to install. If you decide it's not for you, you get the $7 back and keep the scanner for the year.November 16 at 1:00 AM | Profits Run (Ad)BioNexus Launches BGLC 1Lab Pilot for GeneMatrix Workflows at MRNA ScientificNovember 3, 2026 | finance.yahoo.comBioNexus Launches New Corporate Website with Expanded Business and Investor ResourcesOctober 30, 2026 | globenewswire.comBioNexus to Build AI Applications for Malaysian Healthcare Under Exclusive CogniAI LicenceOctober 7, 2026 | globenewswire.comRuanyun To License Cogni AI To BioNexus For Malaysian Healthcare ExpansionOctober 6, 2026 | rttnews.comRYET to Enter Malaysian Healthcare Through Exclusive Cogni AI License to BioNexus Gene LabOctober 5, 2026 | markets.businessinsider.comSee More Headlines BGLC Stock Analysis - Frequently Asked Questions How have BGLC shares performed this year? BioNexus Gene Lab's stock was trading at $4.1150 at the beginning of 2026. Since then, BGLC shares have decreased by 80.0% and is now trading at $0.8210. How were BioNexus Gene Lab's earnings last quarter? BioNexus Gene Lab Corp. (NASDAQ:BGLC) posted its quarterly earnings results on Tuesday, April, 14th. The company reported ($0.52) EPS for the quarter. The company had revenue of $483.76 thousand for the quarter. BioNexus Gene Lab had a negative net margin of 82.38% and a negative trailing twelve-month return on equity of 32.92%. When did BioNexus Gene Lab's stock split? BioNexus Gene Lab's stock reverse split before market open on Monday, April 7th 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, April 6th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did BioNexus Gene Lab IPO? BioNexus Gene Lab (BGLC) raised $5 million in an IPO on Thursday, July 20th 2023. The company issued 1,300,000 shares at a price of $4.00 per share. Network 1 Financial Securities acted as the underwriter for the IPO. How do I buy shares of BioNexus Gene Lab? Shares of BGLC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/14/2026Today11/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 BGLC's financial health is in the Red zone, according to TradeSmith. BGLC has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorIndustrials Industry Trading Companies & Distributors Sub-IndustryTrading Companies & Distributors Current SymbolNASDAQ:BGLC CIK1737523 Webwww.bionexusgenelab.com Phone60-1-2212-6512FaxN/AEmployees19Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$2.98 million Net Margins-82.38% Pretax Margin-82.38% Return on Equity-32.92% Return on Assets-29.75% Debt Debt-to-Equity Ratio0.01 Current Ratio6.08 Quick Ratio5.28 Sales & Book Value Annual Sales$3.13 million Price / Sales0.72 Cash FlowN/A Price / Cash FlowN/A Book Value$3.56 per share Price / Book0.22Miscellaneous Outstanding Shares2,933,000Free Float2,932,000Market Cap$2.25 million OptionableNot Optionable Beta4.28 The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:BGLC) was last updated on 11/16/2026 by MarketBeat.com Staff. From Our PartnersMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment t...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredThis Could Be the Biggest Monetary Shift in 50 YearsThe U.S. government still values its gold reserves at $42 an ounce, a price set by Congress in 1973. Gold trad...Patriot Gold Group | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredBeginner’s Guide to GoldThe Ultimate Beginner's Guide to Gold IRAs Protect Your Retirement Savings Before It's Too Late With This I...Goldco Direct, LLC | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioNexus Gene Lab Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioNexus Gene Lab With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.